Wyden, Stabenow, Senators Call for Review of Trump’s Tax Returns in Light of Ongoing Russia-Trump Associates Investigations
WASHINGTON, D.C. – U.S. Senator Debbie Stabenow (D-MI), Senate Finance Committee Ranking Member Ron Wyden (D-OR), and other Democratic Members of the Senate Finance Committee today sent a letter urging Senate Finance Committee Chairman Orrin Hatch (R-UT) to allow Committee members to review President Trump’s tax returns, in light of the ongoing investigation into ties […]
Wyden Statement on President’s Trade Agenda
WASHINGTON – Senate Finance Committee Ranking Member Ron Wyden, D-Ore., issued the following statement on the President’s Trade Agenda released today: “While many of the president’s stated objectives are laudable, it is troubling that the President’s Trade Agenda still leaves the American people in the dark about the actions he intends to take on trade. […]
Wyden Statement at Finance Committee Markup of Seema Verma’s Nomination to Lead CMS
Two weeks ago, when Ms. Verma was before the Finance Committee, I said I would need better answers than she provided in the hearing. These were not “gotcha” questions. They were questions that go to the core of what it means to be CMS administrator: • How would you use your authority to help doctors […]
Senate Democrats Question Legality of Secretary Tillerson Ethics Plan, Call for Administration to Close Abusive Tax Loopholes
WASHINGTON – Senate Finance Committee Ranking Member Ron Wyden, D-Ore., along with members of the committee Senator Tom Carper, D-Del., and Senator Sherrod Brown, D-Ohio, today raised serious concerns about Secretary of State Rex Tillerson’s deal that will allow him to defer paying tens of millions of dollars in federal taxes over the next decade. […]
House, Senate Bill Would Require Trump to Disclose Foreign Business Interests Before Taking Trade Actions
WASHINGTON – A group of 45 Senate and House members today introduced a bill requiring the president to publicly disclose any financial interests that would be at stake before acting on trade matters. Senate Finance Committee Ranking Member Ron Wyden, D-Ore., and House Ways and Means Committee Ranking Member Richard Neal, D-Mass., led the bicameral […]
Wyden and Murray Release Statements on Proposed CMS Marketplace Rule
WASHINGTON – Senate Finance Committee Ranking Member Ron Wyden, D-Ore., and Senate Health, Education, Labor, and Pensions (HELP) Committee Ranking Member Patty Murray, D-Wash., today issued statements following the release of a proposed Centers for Medicare & Medicaid Services (CMS) rule related to the individual and small group health insurance markets: “Today’s rule sends a […]
Wyden Speaks on Senate Floor in Opposition of Steven Mnuchin’s Nomination to Lead the Treasury Department
WASHINGTON – Senate Finance Committee Ranking Member Ron Wyden, D-Ore., delivered a statement on the Senate floor tonight in opposition of Steven T. Mnuchin’s nomination to be the Secretary of the Treasury. “In just a few minutes, this body will vote to confirm as Treasury Secretary Steven Mnuchin, the former head of one of the […]
Wyden Statement on Senate Floor on Steven Mnuchin to be Treasury Secretary
The Senate is now debating the nomination of Steven Mnuchin to be Treasury Secretary. And this is yet another nomination on which the majority has walked away from a 20 year, bipartisan approach when it comes to the vetting process. In 2009 when Tim Geithner was President Obama’s first Treasury nominee, a vetting issue came […]
Wyden Statement on Tom Price’s Nomination to Lead HHS
WASHINGTON – Senate Finance Committee Ranking Member Ron Wyden, D-Ore., today offered the following statement before the Senate confirmed Congressman Tom Price to be the Secretary of the Department of Health and Human Services: Wyden’s full statement before the vote can be found below: The debate on Congressman Price’s nomination is a referendum on the […]
Wyden Statement on Senate Floor on HHS Nominee Tom Price’s Unanswered Ethical and Legal Questions Regarding Stock Trades
Introduction The stock trades Congressman Price made while working on healthcare policy raise serious ethical and legal questions that deserve further inquiry. But none of Congressman Price’s stock trades raise more questions than the hundreds of thousands of shares he bought in the obscure Australian biotech company, Innate Immunotherapeutics, so let’s start there. His stock […]